Neutralizing anti-IFN-β antibodies -: How much more evidence do we need to use them in practice?

被引：29
作者：
Giovannoni, G
Goodman, A
机构：
[1] UCL, Neurol Inst, Dept Neuroinflammat, London WC1N 3BG, England
[2] Univ Rochester, Dept Neurol, Neuroimmunol Unit, Rochester, NY USA
来源：
NEUROLOGY | 2005年 / 65卷 / 01期
关键词：
D O I：
10.1212/01.wnl.0000172080.54415.f1
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：6 / 8
页数：3
相关论文
共 16 条
[11]   Neutralizing antibodies and efficacy of interferon β-1a -: A 4-year controlled study [J].
Kappos, L ;
Clanet, M ;
Sandberg-Wollheim, M ;
Radue, EW ;
Hartung, HP ;
Hohlfeld, R ;
Xu, J ;
Bennett, D ;
Sandrock, A ;
Goelz, S .
NEUROLOGY, 2005, 65 (01) :40-47
[12]   Neutralizing antibodies reduce the efficacy of βIFN during treatment of multiple sclerosis [J].
Malucchi, S ;
Sala, A ;
Gilli, F ;
Bottero, R ;
Di Sapio, A ;
Capobianco, M ;
Bertolotto, A .
NEUROLOGY, 2004, 62 (11) :2031-2037
[13]   Randomized, comparative study of interferon β-1a treatment regimens in MS -: The EVIDENCE trial [J].
Panitch, H ;
Goodin, DS ;
Francis, G ;
Chang, P ;
Coyle, PK ;
O'Connor, P ;
Monaghan, E ;
Li, D ;
Weinshenker, B .
NEUROLOGY, 2002, 59 (10) :1496-1506
[14]   The clinical impact of interferon beta antibodies in relapsing-remitting MS [J].
Perini, P ;
Calabrese, M ;
Biasi, G ;
Gallo, P .
JOURNAL OF NEUROLOGY, 2004, 251 (03) :305-309
[15]   Appearance and disappearance of neutralizing antibodies during interferon-beta therapy [J].
Sorensen, PS ;
Koch-Henriksen, N ;
Ross, C ;
Clemmesen, KM ;
Bendtzen, K .
NEUROLOGY, 2005, 65 (01) :33-39
[16]   Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis [J].
Sorensen, PS ;
Ross, C ;
Clemmesen, KM ;
Bendtzen, K ;
Frederiksen, JL ;
Jensen, K ;
Kristensen, O ;
Petersen, T ;
Rasmussen, S ;
Ravnborg, M ;
Stenager, E ;
Koch-Henriksen, N .
LANCET, 2003, 362 (9391) :1184-1191
12